"Lucentis, which is made by Roche unit Genentech and administered by monthly injection, is already approved for two other eye ailments."
That was taken from an article just released on Yahoo news about two treatments that eye specialists condone, on July 25th, 2012.
Sounds just like ACTC's methodology.
ACTC is not developing a drug. They are developing a LIVE stem cell treatment that has the potential to, and has been proven to reverse the eye disease. Those 2 drugs are just that, drugs. Drugs that need to be administered routinely. Drugs that do not cure or reverse the disease, but MAY inhibit the disease progression. So Roche didn't beat anyone anywhere, they aren't even in the same league.
WASHINGTON (Reuters) - A U.S. Food and Drug Administration panel on Thursday recommended two drugs for combating different forms of vision loss that can lead to blindness among a range of adults, including diabetics and the elderly.
The FDA advisory committee of outside experts gave its support to Swiss-based Roche Holding AG's Lucentis eye drug for treatment of diabetic macular edema and Belgium-based ThromboGenics' treatment for viteromacular adhesion, a condition that often develops with aging.
The recommendations will now be considered by FDA regulators as they decide whether to approve the two injectable drugs for sale in the United States.
The news emerged after the companies' shares had ended trading in Europe. Roche shares closed slightly higher at 168 Swiss francs, while ThromboGenics fell 4.82 percent to 23.30 euros.
The panel gave its blessing to both 0.3 milligram and 0.5 milligram doses of Roche's drug, known generically as ranibizumab, after reviewing clinical research showing it clearly helps diabetic patients who suffer from diabetic macular edema, or DME.
Tls, three possibilities here.
1. You're a basher trying to keep the price down.
2. You're an idiot that doesn't know anything trying to make a point?
3. You're both.
You just made my ignore list posting this crap but don't worry, you'll have a lot of company.
Roche/Genetech treats "wet" and not "dry" AMD. "Wet" AMD is about 20 percent of AMD, while "dry" AMD is about 80 percent of AMD.
There is still lacking really good treatments for "dry" AMD, which is about 80% of AMD.
not too mention risk of infection if you half to continously inject, avastin,lucentis both require that anyone who knows anything about ACTC has known about those drugs for a long time and can't even begin to compare with RPE cells if the outcome reaches it's positive potential